4SC (VSC) Q3 2024 earnings summary

Executive summary

• Focused on advancing and commercializing resminostat (Kinselby) for advanced CTCL, with EMA marketing approval pending and orphan drug status granted in Switzerland, EU, and US.

• Completed pivotal RESMAIN study showing positive results for resminostat as maintenance therapy in advanced CTCL.

• Engaged a global investment bank to explore commercialization options for resminostat outside Japan.

Financial highlights

• Cash balance as of 30 September 2024 was €10.36 million, up from €8.32 million at year-end 2023.

• Monthly cash use from operations averaged €600 thousand in the first nine months of 2024, within the forecasted range.

• Secured €4.0 million in gross proceeds from a capital increase in September 2024.

• Additional €3.5 million loan received from main shareholder in July 2024.

Outlook and guidance

• Current funds projected to finance operations into Q1 2026, subject to forecast accuracy and regulatory developments.

• Commercialization of resminostat in the EU, UK, Switzerland, and Japan remains the primary value driver.